Q2 2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: SHANGHAI SERUM BIO-TECHNOLOGY(688163) the Revenue is 77.12 M (+2.55%);the EBIT is 40.7 M (+32.54%);the EPS is 0.22 (-28.72%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.08B2.55%
----
----
EBIT
0.04B32.54%
----
----
EPS
0.220228.72%
----
----
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf